Investigating an Arginase 1⁺ monocyte- macrophage population in driving fibrosis in chronic kidney disease.
dc.contributor.advisor
Denby, Laura
dc.contributor.advisor
Conway, Bryan
dc.contributor.advisor
Benezech, Cecile
dc.contributor.author
Bell, Rachel Mary Buchanan
dc.contributor.sponsor
British Heart Foundation
en
dc.date.accessioned
2024-03-08T15:17:58Z
dc.date.available
2024-03-08T15:17:58Z
dc.date.issued
2024-03-08
dc.description.abstract
Chronic kidney disease (CKD) represents a global health burden of increasing prevalence.
The common pathway in all progressive kidney disease is fibrosis, where scar tissue replaces
normal functioning tissue. Macrophages are a major cellular component of the renal
mononuclear phagocyte system, with roles in defence against infection, renal injury, and
repair. Renal macrophages are derived from foetal precursors and, in adult life, circulating
monocytes, with a greater contribution in response to infection or injury. Macrophages
possess enormous plasticity and heterogeneity; they are known to adopt different phenotypic
and functional characteristics that depend on the local tissue microenvironment and stress
signals (due to tissue insult) and perhaps ontogeny. Hence, they can be injurious or may
mediate repair by scavenging cell debris, degrading excess extracellular matrix and secreting
factors that may promote the regeneration of injured tissue.
Using single-cell RNA sequencing, we have recently identified novel myeloid subsets in
murine reversible, unilateral ureteric obstruction (UUO), an acute non-functional model of
kidney fibrosis and repair. Amongst the subsets, a population of cells was identified
exclusively in acute injury (2 days post-UUO); they transcriptomically align to monocytes but
express Arginase 1 (Arg1) and C-type lectin Clec4d, and many pro-inflammatory and profibrotic
genes. The hypothesis presented in this thesis is that a proportion of monocytes
recruited to the kidney in early injury transition into monocyte-derived macrophages (Mo-
MΦ) with an Arg1⁺ phenotype and have a role in activating inflammation and fibrosis in
kidney disease.
Arg1 and Clec4d were detectable in bulk kidney tissue in different models of renal fibrosis,
including the 5/6ᵗʰ subtotal nephrectomy, UUO and unilateral ischaemic reperfusion injury
(IRI). Further detailed flow cytometry investigations in the UUO and IRI over a seven-day
time course showed persistent recruitment of Ly6Cʰᶦ monocytes transitioning to pro-fibrotic
inflammatory macrophages in injured kidneys. Arg1⁺ Mo-MΦ persisted in the kidney; across
the injury time course, they increased in number and, consistent with a monocyte-tomacrophage
transition, there was a decrease in monocyte markers but an increase in activated
macrophage marker expression in this subset. Arg1 was not detectable in the blood. In
human fibrotic kidney biopsy samples, ARG1 was detected in the classical- and CLEC4D in
the classical and intermediate monocyte populations.
To confirm that Arg1⁺ Mo-MΦ are derived from monocytes, the Ccr2-CreERᵀ²-
TdTomato mouse model was employed, in which tamoxifen administration induces
irreversible labelling of Ccr2⁺ cells, including Ly6Cʰᶦ monocytes and their progeny.
Tamoxifen was administered under a single or multiple-dose regimen following UUO
surgery, showing the Arg1⁺ Mo-MΦ are derived from Ccr2⁺ monocytes in fibrotic injury.
To investigate the therapeutic potential of targeting Clec4d⁺ expressed on the Arg1⁺ Mo-
MΦ, mice underwent UUO surgery and were given multiple doses of a neutralising anti-
Clec4d monoclonal antibody. A decrease in Arg1, Clec4d and fibrosis-related gene expression
was evident by day seven post-injury. Taken together, these data confirm the presence of an
Arg1⁺ Mo-MΦ population in renal injury and fibrosis development in pre-clinical models of
kidney disease and human fibrotic renal biopsies. The Arg1⁺ macrophages in late fibrotic
injury are monocyte-derived, and targeting them via Clec4d neutralisation has the potential
to reduce the extent of renal fibrosis. These findings could be of clinical relevance with the
potential to aid the development of novel therapeutics to limit fibrosis and halt the
progression of CKD.
en
dc.identifier.uri
https://hdl.handle.net/1842/41603
dc.identifier.uri
http://dx.doi.org/10.7488/era/4335
dc.language.iso
en
en
dc.publisher
The University of Edinburgh
en
dc.relation.hasversion
Rachel M.B. Bell, Elisa Villalobos, Mark Nixon, Allende Miguelez-Crespo, Lee Murphy, Angie Fawkes, Audrey Coutts, Matthew G.F. Sharp, Martha V. Koerner, Emma Allan, Onno C. Meijer, Renè Houtman, Alex Odermatt, Katharina R. Beck, Scott G. Denham, Patricia Lee, Natalie Z.M. Homer, Brian R. Walker, Ruth A. Morgan. Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice. Molecular Metabolism. 2021; 48: 101225
en
dc.relation.hasversion
Rachel M.B. Bell & Laura Denby. Myeloid Heterogeneity in Kidney Disease as Revealed through Single-Cell RNA Sequencing. Kidney 360. 2021; 2: 1844-1851
en
dc.relation.hasversion
Rachel M.B. Bell & Bryan R. Conway. Macrophages in the kidney in health, injury and repair. International Review of Cell and Molecular Biology. 2022; 367
en
dc.relation.hasversion
Eoin D. O'Sullivan, Katie J. Mylonas, Rachel M.B. Bell, Cyril Carvalho, David P. Baird, Carolynn Cairns, Kevin Gallagher, Ross A. Campbell, Marie Docherty, Alexander Laird, Neil C. Henderson, Tamir Chandra, Kristina Kirschner, Bryan R. Conway, Gry H. Dihazi, Michael Zeisberg, Jeremy Hughes, Laura Denby, Hassan Dihazi, David A. Ferenbach. Single-cell analysis of senescent epithelia reveals targetable mechanisms promoting fibrosis. JCI Insight. 2022; 7: e154124
en
dc.subject
Arginase 1+ monocytemacrophage
en
dc.subject
fibrosis
en
dc.subject
Chronic kidney disease (CKD)
en
dc.subject
Renal macrophages
en
dc.subject
unilateral ureteric obstruction (UUO)
en
dc.subject
fibrosis in kidney disease
en
dc.subject
Arg1+ Mo-MΦ
en
dc.subject
Ccr2+ monocytes
en
dc.subject
fibrotic injury
en
dc.subject
Clec4d+
en
dc.title
Investigating an Arginase 1⁺ monocyte- macrophage population in driving fibrosis in chronic kidney disease.
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
Files
Original bundle
1 - 1 of 1
- Name:
- BellRMB_2024.pdf
- Size:
- 47.36 MB
- Format:
- Adobe Portable Document Format
- Description:
This item appears in the following Collection(s)

